The Latest Cardiac and Vascular News
VANCOUVER and MINNEAPOLIS, Feb. 04, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc Reducer™ (“Reducer”). The two analyses, authored by Americo Cicchetti, Graduate School of Health Economics and Management (ALTEMS) at the Catholic University […]
PDUFA Target Action Date Set for November 30, 2022 FDA is Currently Not Planning to Hold an Advisory Committee Meeting to Discuss the Application SOUTH SAN FRANCISCO, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted and […]
Reports Fourth Quarter Revenues of $12.0 Billion; Full-Year Revenues of $46.4 Billion Posts Fourth Quarter Earnings Per Share of $1.07 and Non-GAAP EPS of $1.83; Posts Full-Year Earnings Per Share of $3.12 and Non-GAAP EPS of $7.51 Delivers Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios Advances Pipeline with […]
Conference Call Scheduled for Today, February 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $59.1 million increased 1.3% sequentially compared to first quarter this year and decreased 7.8% compared to second quarter last year Procedure volumes adversely impacted by hospital constraints and staffing shortages caused by Covid-19 […]
STOCKHOLM, Feb. 3, 2022 /PRNewswire/ — Continued strength with net sales growth above 30% despite the pandemic Fourth quarter (October-December 2021) Order intake amounted to 73.7 (73.1) MSEK. Net sales amounted to 67.7 (45.9) MSEK. Operating income for the period before depreciations (EBITDA) totalled 12.0 (4.3) MSEK. Net income for the period amounted […]
– Revenue in the fourth quarter of 2021 increased 8 percent, driven by volume growth of 11 percent. Excluding COVID-19 antibodies, fourth-quarter 2021 revenue grew 6 percent. – Full-year 2021 revenue increased 15 percent, driven by volume growth of 16 percent. Excluding COVID-19 antibodies, full-year 2021 revenue grew 10 percent. […]
SUNNYVALE, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell Therapy System for the treatment of heart failure. It is believed […]
Ontario, Canada, Feb. 03, 2022 (GLOBE NEWSWIRE) — Kitchener, ON – February 3, 2022– Vena Medical is excited to announce the first Health Canada Medical Device License for their new product, the Vena Balloon Distal Access Catheter™[1] (BDAC). The Vena BDAC™ combines the balloon guide catheters and distal access catheters that are currently […]
AnaCardio exercises option to license a program in heart failure from Helsinn Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, are pleased to announce that AnaCardio has […]
LIVMOR to Develop HeartBeam Branded Version of the FDA Registered LIVMOR Halo+ Portal SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has signed a partnership agreement with LIVMOR Inc., a digital health […]
